A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults

Vaccine

Volumn 18, Issue 20, 2000, Pages 2075-2082

  Van Der Wielen, M ^a   Van Damme, P ^a   Joossens, E ^a   Francois G ^a   Meurice, F ^b   Ramalho, A ^b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Adult immunisation; Pertussis; Vaccines

Indexed keywords

ANTIGEN; DIPHTHERIA ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS VACCINE; HEMAGGLUTININ; PERTACTIN; PERTUSSIS VACCINE; TEDIVAX; TETANUS ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPHTHERIA; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; IMMUNOGENICITY; INJECTION PAIN; MALE; NORMAL HUMAN; PERTUSSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TETANUS;

ADHESINS, BACTERIAL; ADULT; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL OUTER MEMBRANE PROTEINS; BORDETELLA PERTUSSIS; CLOSTRIDIUM TETANI; CORYNEBACTERIUM DIPHTHERIAE; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; EDEMA; ERYTHEMA; FATIGUE; FEMALE; HEMAGGLUTININS; HUMANS; IMMUNIZATION, SECONDARY; MALE; PAIN; PERTUSSIS TOXIN; SINGLE-BLIND METHOD; TIME FACTORS; VACCINATION; VIRULENCE FACTORS, BORDETELLA; VOMITING;

EID: 0034106906     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00568-X     Document Type: Article

References (49)

1. Davey S. The vaccine challenge. State of the world's vaccines and immunization. 1996;1-25 World Health Organisation and United Nations Children's Fund, Geneva.
2. Giammanco A., Chiarini A., Stroffolini T., et al. Seroepidemiology of pertussis in Italy. Rev. Infect. Dis. 13:1991;1216-1220.
3. Keitel W.A., Edwards K.M. Pertussis in adolescents and adults: time to reimmunize? Semin. Respir. Infect. 10:1995;51-57.
4. Nennig M.E., Shinefield H.R., Edwards K.M., Black S.B., Fireman B.H. Prevalence and incidence of adult pertussis in an urban population. JAMA. 275:1996;1672-1674.
5. Centres for Disease Control. Resurgence of Pertussis in the United States 1993. Morbid Mortal. Wkly. Rep. 42:1993;952-960.
6. Baron S., Njamkepo E., Grimprel E., et al. Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination. Pediatr. Infect. Dis. J. 17:1998;412-418.
7. Cherry J.D., Baraff L.J., Hewlett E. The past, present and future of pertussis. The role of adults in epidemiology and future control. West. J. Med. 150:1989;319-328.
8. Mortimer E.A. Jr. Pertussis and its prevention: a family affair. J. Infect. Dis. 161:1990;473-479.
9. Bass J.W., Wittler R.R. Return of epidemic pertussis in the United States. Pediatr. Infect. Dis. J. 13:1994;343-345.
10. Hoppe J.E. Update on epidemiology, diagnosis, and treatment of pertussis. Eur. J. Clin. Microbiol. Infect. Dis. 15:1996;189-193.
11. Fine P.E. Adult pertussis: a salesman's dream-and an epidemiologist's nightmare. Biologicals. 25:1997;195-198.
12. Deville J.G., Cherry J.D., Christenson P.D., et al. Frequency of unrecognized Bordetella pertussis infections in adults. Clin. Infect. Dis. 21:1995;639-642.
13. Statement on management of persons exposed to pertussis and pertussis outbreak control. Can. Med. Assoc. J. 152:1995;712-716.
14. Decker M.D., Edwards K.M., Steinhoff M.C., et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics. 96:1995;557-566.
15. Pichichero M.E. Acellular pertussis vaccines. Towards an improved safety profile. Drug Saf. 15:1996;311-324.
16. Kimura M., Kuno-Sakai H., Sato Y., et al. A comparative trial of the reactogenicity and immunogenicity of Takeda acellular pertussis vaccine combined with tetanus and diphtheria toxoids. Outcome in 3- to 8-month-old infants, 9- to 23-month-old infants and children, and 24- to 30-month-old children. Am. J. Dis. Child. 145:1991;734-741.
17. UpdateVaccine side effects, adverse reactions, contraindications, and precautions. Morbid Mortal. Wkly. Rep. 45:(RR12):1996;1-35.
18. Tran Minh N.N., Edelman K., He Q., Viljanen M.K., Arvilommi H., Mertsola J. Antibody and cell-mediated immune responses to booster immunization with a new acellular pertussis vaccine in school children. Vaccine. 16:1998;1604-1610.
19. Dagan R., Igbaria K., Piglansky L., Van Brusteghem F., Melot V., Kaufhold A. Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccines as a booster in 4-7-year-old children primed with diphtheria-tetanus-whole cell pertussis vaccine before 2 years of age. Vaccine. 17:1999;2620-2627.
20. Granström M., Thoren M., Blennow M., Tiru M., Sato Y. Acellular pertussis vaccine in adults: adverse reactions and immune response. Eur. J. Clin. Microbiol. 6:1987;18-21.
21. Kanra G., Ceyhan M., Vandevoorde D., Bogaerts H. Acellular pertussis diphtheria-tetanus-pertussis vaccine containing separately purified pertussis toxoid, filamentous haemagglutinin and 69 kDa outer membrane protein as a booster in children. Eur. J. Pediatr. 152:1993;478-483.
22. Camargo M.E., Silveira L., Furuta J.A., Oliveira E.P., Germek O.A. Immunoenzymatic assay of anti-diphtheric toxin antibodies in human serum. J. Clin. Microbiol. 20:1984;772-774.
23. Melville-Smith M.E., Seagroatt V.A., Watkins J.T. A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera. J. Biol. Stand. 11:1983;137-144.
24. Miyamura K., Nishio S., Ito A., Murata R., Kono R. Micro cell culture method for determination of diphtheria toxin and antitoxin titres using Vero cells. I. Studies on factors affecting the toxin and antitoxin titration. J. Biol. Stand. 2:1974;189-201.
25. Miyamura K., Tajiri E., Ito A., Murata R., Kono R. Micro cell culture method for determination of diphtheria toxin and antitoxin titres using Vero cells. II. Comparison with the rabbit skin method and practical application for seroepidemiological studies. J. Biol. Stand. 2:1974;203-209.
26. World Health Organization 1989. Second meeting of national programme managers on the Expanded Programme on Immunization, 1989 May, Istanbul, Turkey, Report EUR/ICP/EPI 021 1905 r.
27. World Health Organization 1990. The control of diphtheria in Europe; 1990 April, Geneva, Switzerland. Report EUR/ICP/EPI 024 5582 r.
28. Pasetti M., Eriksson P., Ferrero F., Manghi M. Serum antibodies to diphtheria-tetanus-pertussis vaccine components in Argentine children. Infection. 25:1997;339-345.
29. Stark K., Schönfeld C., Barg J., Molz B., Vornwald A., Bienzle U. Seroprevalence and determinants of diphtheria, tetanus and poliomyelitis antibodies among adults in Berlin, Germany. Vaccine. 17:1999;844-850.
30. Liese J.G., Stojanov S., Belohradsky B.H. Pertussis vaccination with acellular vaccines. Tolerance-effectiveness - current vaccination recommendations. Fortschr. Med. 115:1997;22-27.
31. Anderson R.M., May R.M. Immunisation and herd immunity. Lancet. 335:1990;641-645.
32. Hadler S.C. Cost benefit of combining antigens. Biologicals. 22:1994;415-418.
33. Begue P., Grimprel E. Future combined vaccines. J. Infect. Dis. 174:(Suppl 3):1996;S295-S297.
34. Storsaeter J., Hallander H.O., Gustafsson L., Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine. 16:1998;1907-1916.
35. Cherry J.D., Gornbein J., Heininger U., Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine. 16:1998;1901-1906.
36. Greco D., Salmaso S., Mastrantonio P., et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N. Engl. J. Med. 334:1996;341-348.
37. Salmaso S., Mastrantonio P., Wassilak S.G.F., et al. Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines. Vaccine. 16:1998;1270-1275.
38. Schmitt H.J., Wirsing von König C.H., Neiss A., et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA. 275:1996;37-41.
39. Schmitt H.J., Schuind A., Knuf M., et al. Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants. J. Pediatr. 129:1996;695-701.
40. Wassilak S.G.F., Orenstein W.A., Sutter R.W. Tetanus toxoid. Plotkin S.A., Mortimer E.A. Jr. Vaccines. 2nd ed. 1994;57-90 Saunders, Philadelphia.
41. Simonsen O., Klærke M., Klærke A., et al. Revaccination of adults against diphtheria. II: Combined diphtheria and tetanus revaccination with different doses of diphtheria toxoid 20 years after primary vaccination. Acta. Pathol. Microbiol. Immunol. Scand. 94:1986;219-225.
42. Aggerbeck H., Fenger C., Heron I. Booster vaccination against diphtheria and tetanus in man. Comparison of calcium phosphate and aluminium hydroxide as adjuvants - II. Vaccine. 13:1995;1366-1374.
43. Aggerbeck H., Wantzin J., Heron I. Booster vaccination against diphtheria and tetanus in man. Comparison of three different vaccine formulations - III. Vaccine. 14:1996;1265-1272.
44. Dal-Re R., Gil A., Gonzalez A., Lasheras L. Does tetanus immune globulin interfere with the immune response to simultaneous administration of tetanus-diphtheria vaccine? A comparative clinical trial in adults. J. Clin. Pharmacol. 35:1995;420-425.
45. Galazka A.M., Robertson S.E. Immunization against diphtheria with special emphasis on immunization of adults. Vaccine. 14:1996;845-857.
46. Matheï C., Van Damme P., Bruynseels P., Goossens H., Vranckx R., Meheus A. Diphtheria immunity in Flanders. Eur. J. Clin. Microbiol. Infect. Dis. 16:1997;631-636.
47. Cohen D., Green M.S., Katzenelson E., Slepon R., Bercovier H., Wiener M. Long-term persistence of anti-diphtheria toxin antibodies among adults in Israel. Eur. J. Epidemiol. 10:1994;267-270.
48. Mortimer E.A. Jr. Diphtheria Toxoid. Plotkin S.A., Mortimer E.A. Jr. Vaccines. 2nd ed. 1994;41-56 Saunders, Philadelphia.
49. Hederstedt B., Granström M. Adverse reactions and antibody response to an acellular pertussis toxoid vaccine in adult volunteers. Vaccine. 7:1989;349-350.